HIV-associated neurocognitive disorder (HAND) remains highly prevalent in HIV infected individuals and represents a special group of neuropathological disorders, which are associated with HIV-1 viral proteins, such as transactivator of transcription (Tat) protein. Cocaine abuse increases the incidence of HAND and exacerbates its severity by enhancing viral replication. Perturbation of dopaminergic transmission has been implicated as a risk factor of HAND. The presynaptic dopamine (DA) transporter (DAT) is essential for DA homeostasis and dopaminergic modulation of the brain function including cognition. Tat and cocaine synergistically elevate synaptic DA levels by acting directly on human DAT (hDAT), ultimately leading to dysregulation of DA transmission. Through integrated computational modeling and experimental validation, key residues have been identified in hDAT that play a critical role in Tat-induced inhibition of DAT and induce transporter conformational transitions. This review presents current information regarding neurological changes in DAT-mediated dopaminergic system associated with HIV infection, DAT-mediated adaptive responses to Tat as well as allosteric modulatory effects of novel compounds on hDAT. Understanding the molecular mechanisms by which Tat induces DATmediated dysregulation of DA system is of great clinical interest for identifying new targets for an early therapeutic intervention for HAND.
Introduction
HIV infection continues to be a major global public health issue with an estimated thirty-five million people worldwide living with HIV. Despite the widespread use of efficacious antiretroviral therapies to control peripheral HIV infection and improve the life of HIV patients, more than 50% of HIV-1 positive individuals suffer from neurological complications collectively referred to as HIV-associated neurocognitive disorder (HAND) (Heaton et al., 2010) . HIV can enter the brain and produce proviral DNA by viral replication in the early stage of HIV infection, which contribute to the development of HAND (Nath & Clements, 2011; Smith, Auwaerter, Knowlton, Saylor, & McArthur, 2017) . Since antiretroviral medications cannot cross the blood-brain barrier while infected monocytes carrying HIV can (Burdo, Lackner, & Williams, 2013; McArthur, Steiner, Sacktor, & Nath, 2010; Saylor et al., 2016) , HIV replication and production of viral proteins can be persistent in the brain of HIV infected patients treated with combination antiretroviral therapy (cART). Most HAND patients experience cognitive, memory, motor, and behavioral deficits (Gartner, 2000; McArthur et al., 2004; Rackstraw, 2011) . The HAND patients present the neuropathological conditions and neurocognitive deficits that emerge from the continuous exposure of the CNS to HIV-1, viral proteins, immune inflammation, and cART (BrackWerner, 1999; Clifford & Ances, 2013; Frankel & Young, 1998; Johnston et al., 2001; King, Eugenin, Buckner, & Berman, 2006; Power et al., 1998) . Among the viral proteins, transactivator of transcription (Tat) protein plays a crucial role in the neurotoxicity and cognitive impairment evident in neuroAIDS (King et al., 2006; Rappaport et al., 1999) . Importantly, drugs of abuse, such as cocaine, have been shown to increase the incidence of HAND and its severity by enhancing viral replication (Ferris, Mactutus, & Booze, 2008; Nath, Maragos, Avison, Schmitt, & Berger, 2001) . Currently, there are no promising therapeutic strategies for HAND. Considering the progressive and neurodegenerative nature of HAND, establishing an early intervention strategy would be beneficial to the preservation of neurocognitive function in HIV-infected individuals.
Converging lines of clinical observations, supported by imaging (Chang et al., 2008; Wang et al., 2004) , neuropsychological http://dx.doi.org/10.1016/j.pharmthera. 2017.10.007 performance testing (Kumar, Ownby, Waldrop-Valverde, Fernandez, & Kumar, 2011; Meade, Lowen, MacLean, Key, & Lukas, 2011) , and postmortem examinations (Gelman et al., 2012) , have implicated the dysregulation of dopamine (DA) system with the abnormal neurocognitive function observed in HAND (Berger & Arendt, 2000; Purohit, Rapaka, & Shurtleff, 2011) . The presynaptic DA transporter (DAT)-mediated DA reuptake is essential for normal DA homeostasis and dopaminergic modulation of the brain function including attention, learning, memory, and motivation. In vitro, the interplay of Tat and cocaine augments synaptic DA levels and Tat release by inhibiting DAT activity (Ferris, Frederick-Duus, Fadel, Mactutus, & Booze, 2010; Zhu, Mactutus, Wallace, & Booze, 2009) . Prolonged exposure to Tat protein eventually causes DAT-mediated dysregulation of DA to accelerate the progression of HAND (Gaskill, Miller, Gamble-George, Yano, & Khoshbouei, 2017; Purohit et al., 2011) . Indeed, human DA transporter (hDAT) activity is strikingly reduced in HIV-1-infected cocaine-using patients, correlating with the severity of HIV-1 associated cognitive deficits (Chang et al., 2008; Wang et al., 2004) . However, the molecular mechanisms underlying HIV infection-impaired DA transport process are still largely unclear. Therefore, there is a pressing need to define the molecular mechanism(s) by which the impaired DA system by HIV-1 infection affects the progression of HAND in concurrent cocaine abusers. The recently published work has demonstrated that Tatinduced inhibition of DAT is mediated by binding to allosteric binding site(s) on DAT, not by interacting with the DA uptake site Zhu et al., 2009; Zhu, Ananthan, Mactutus, & Booze, 2011) . Accordingly, attenuating Tat binding to DAT would be expected to have minimal influence on physiological DA transport. To achieve these goals, a greater understanding of the intermolecular interactions between Tat and hDAT is needed, which involves identifying key residues in hDAT with which Tat interacts and the mechanisms by which Tat induces inhibition of DA transport. This review focuses on recent investigations regarding neurological changes in DAT-mediated dopaminergic system associated with HIV infection, DAT-mediated adaptive responses to Tat as well as allosteric modulatory effects of novel compounds on hDAT.
2. Viral protein, dopamine system and HIV-associated neurocognitive disorder
HIV-1 viral proteins
Viral replication and proviral DNA induction within the central nervous system (CNS) in the early HIV-1 infection (Nath & Clements, 2011) have been implicated as a risk determinant of HAND (Berger & Arendt, 2000; Purohit et al., 2011) . Since most antiretroviral therapy medications cannot cross the blood-brain barrier (Buckner, Luers, Calderon, Eugenin, & Berman, 2006) , these medications have no influence on the production of viral proteins in the CNS. Therefore, viral proteins are associated with the persistence of HIV infection-induced neuropathology and subsequent cognitive deficits (BrackWerner, 1999; Frankel & Young, 1998; Johnston et al., 2001; Power et al., 1998) . The HIV genome contains three major genes, 5′gag-polenv-3′, encoding major structural proteins as well as essential enzymes (Shrivastav et al., 2008) . Proteins encoded by the HIV genome are classified as 1) viral structure proteins, Gag polyprotein, Pol polyproteins, and envelop proteins, gp120 and gp41; 2) essential regulatory proteins, Tat and Rev; and 3) accessory regulatory proteins, nef, vpr, vif and vpu (King, 1994) . Among the viral proteins, Tat protein plays a crucial role in regulating the reverse transcription of viral genome RNA, ensuring efficient synthesis of viral mRNAs (Shrivastav et al., 2008) . Tat is a nonstructural viral protein that is encoded from the first and second exons comprised of amino acids 1-72 and 73-101, respectively. Tatinduced neurotoxicity primarily contributes to HIV infection associated cognitive impairment evident in neuroAIDS (King et al., 2006; Rappaport et al., 1999) . Tat is secreted from HIV infected cells (Ensoli, Barillari, Salahuddin, Gallo, & Wong-Staal, 1990 ) and further taken up by the surrounding microglia and neurons (Ensoli et al., 1993) . Tat can be detected in DA-rich brain area (basal ganglia and related structure) (Del Valle et al., 2000; Hudson et al., 2000; Lamers et al., 2010) and in the sera (Westendorp et al., 1995; Xiao et al., 2000) of HIV-1 infected patients. However, it is still not clear what the actual biological concentration of Tat (for producing effects on DAT activity) is at or around the synapse or how this effective concentration of Tat might be reflected in cerebrospinal fluid of HIV-infected patients.
Dysregulation of dopaminergic neurotransmission
DA-rich brain regions (basal ganglia and related structures) are highly susceptible to the effects of both HIV infection and substance use. Long-term exposure to HIV viral proteins impairs the central dopaminergic transmission (Berger & Arendt, 2000; Koutsilieri, Sopper, Scheller, ter Meulen, & Riederer, 2002; Nath, Jankovic, & Pettigrew, 1987) and the brain pathways controlling motivation (Berridge, 2007; Everitt & Robbins, 2005; Wise & Bozarth, 1987) . In the early stage of HIV infection, increased levels of DA and decreased DA turnover are found in the cerebrospinal fluid of therapy-naïve HIV patients in asymptomatic infection (Scheller et al., 2010) , which may contribute to decreased levels of DA in DA-rich brain regions (Kumar et al., 2009 (Kumar et al., , 2011 Sardar, Czudek, & Reynolds, 1996) in the advanced stages of HIV infection. Importantly, HIV-induced elevated levels of extracellular DA in CNS can stimulate viral replication in human macrophages within DA-rich brain regions (Gaskill et al., 2009; Gaskill, Calderon, Coley, & Berman, 2013; Gaskill, Yano, Kalpana, Javitch, & Berman, 2014) , resulting in viral protein release, which has been implicated in the pathophysiology of HAND (Li, Li, Steiner, & Nath, 2009 ). Thus, understanding the molecular mechanism(s) of viral protein-mediated neuropathological changes in HAND is of great scientific and clinical interest.
HIV associated neurocognitive and behavior deficits
HAND is a spectrum of disorders generally divided into three main groups: asymptomatic neurocognitive impairment (ANI; 33%), mild neurocognitive disorders (MND, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , and the more severe albeit rare HIV-associated dementia (HAD; 2-8%) (Heaton et al., 2010; McArthur et al., 2010) . Several risk factors are linked to the development of HAND, including cardiovascular risk factors, age, hepatitis C virus infection, and substances of abuse (Saylor et al., 2016) . Among these factors, comorbidities have been considered as a key factor for cognitive impairment of HAND. In addition, early HIV infection of the CNS is believed to contribute to the development of HAND, and evidence suggests that early infected brain can subsequently serve as a sanctuary for HIV replication, thereby limiting the opportunity for a sterilizing cure or eradication (Fois & Brew, 2015) . For example, during the first weeks of HIV infection, infected monocytes carrying HIV enter the CNS and viral proteins can be produced in macrophages by viral replication. Macrophages, the major type of infected cells in the brain, can become HIV reservoirs in the brain and promote inflammation and neuronal damage (Carvallo et al., 2017) . Previous studies showed that elevated DA levels can increase HIV entry into human macrophages and HIV replication, thereby stimulating Tat release from the infected cells (Gaskill et al., 2014) . It has been highlighted that cocaine and Tat protein synergistically elevate DA levels by inhibiting DAT function (Gaskill et al., 2017; Purohit et al., 2011) . Although numerous studies show a variety of potential biomarkers for HAND, the majority of these are associated with HAD rather than ANI and MND, which are most common forms of cognitive impairment (Saylor et al., 2016) . Thus, further understanding of the underlying molecular mechanisms and the differences in biomarkers across the spectrum of HAND will ultimately facilitate the identification and development of precision therapeutics for early stage of HAND.
Identifying Tat binding sites on human dopamine transporter
Clinically, Wang et al. (2004) reported that HIV infected patients with associated dementia had significantly lower DAT availability in putamen and ventral striatum, which is the first evidence of decreased DAT associated with the pathogenesis of HIV dementia (Wang et al., 2004) . Moreover, the decreased DAT in the basal ganglia was greater in HIV patients with comorbid cocaine use than HIV dementia patients (Chang et al., 2008) , which is correlated with impaired learning and memory performance (Hsieh et al., 2010; Mozley, Gur, Mozley, & Gur, 2001) . In contrast to the decreased DAT, one study on postmortem brain tissue from HAND patients (Gelman, Spencer, Holzer, & Soukup, 2006) reported increased levels of DAT expression in the striatum. Thus, the distinct and opposing patterns of HIV infection associated alteration of DAT expression suggest that different stages of HIV infection with or without substance use may influence DAT levels. Further studies to extensively examine the neuropathological changes in DAT expression and activity in HIV infected individuals including all factors such as the stages of HIV infection, age, and substance use, are warranted. Nevertheless, these clinical observations suggest that developing neuroprotective agents that protect dopaminergic system from HIV infection associated DAT impairments would be beneficial to the preservation of neurocognitive function in HIV-infected individuals.
Since HIV does not infect rodents, several approaches have been used for studying the effects of viral proteins on DAT function and DATmediated effects through: 1) rodent brain tissues or cells expressing human DAT in the presence of recombinant Tat 1-86 (Midde et al., 2013 Perry et al., 2010; Quizon et al., 2016; Wallace, Dodson, Nath, & Booze, 2006; Zhu et al., 2009) ; 2) intra-brain region infusion of recombinant Tat (Harrod, Mactutus, Fitting, Hasselrot, & Booze, 2008; Zhu, Midde, Gomez, Sun, & Harrod, 2015) ; 3) doxycycline-induced Tattransgenic (iTat) mouse model (Kim et al., 2003; Perry et al., 2010) ; and 4) HIV-1 transgenic rat model (Ray et al., 2003; Reid et al., 2001; Zhu et al., 2016) . In vitro exposure of rat striatal synaptosomes or cells expressing hDAT to recombinant Tat 1-86 (140-500 nM, final concentration) displays a decrease in [ 3 H]DA uptake in a concentration dependent manner (Midde et al., 2013 Quizon et al., 2016; Zhu et al., 2009) . Intrastriatal bilateral injection of 15 μg/μl of recombinant Tat 1-72 significantly enhances cocaine-induced total activity and alters the development of cocaine-mediated behavioral sensitization in rats (Harrod et al., 2008 ). An in vivo microdialysis study reported that intraaccumbal infusion of recombinant Tat 1-86 (4 μg/μl) significantly reduces DAT-mediated uptake/release efficiency in rats (Ferris, Frederick-Duus, Fadel, Mactutus, & Booze, 2009 ). Furthermore, intraventral tegmental area recombinant Tat 1-86 (10 μg/μl) alters the mesocorticolimbic ERK and CREB signaling in rats . These findings suggest that in vivo exposure of Tat disrupts the mesocorticolimbic pathways, which is consistent with the previous studies (Bansal et al., 2000; Zauli et al., 2000) . With regard to genetically expressing viral proteins in animal models, DAT function and expression are altered in the HIV-1Tg rats . Recently, McIntosh, Sexton, Pattison, Childers, and Hemby (2015) reported that HIV-1Tg rats exhibit a greater affinity for the binding of cocaine to DAT compared to control Fisher 344 rats (McIntosh et al., 2015) . iTat mouse model utilizes a "tetracycline-on" system coupled to Tat 1-86 protein coding gene that becomes transcriptionally active Tat when doxycycline is present (Kim et al., 2003; Perry et al., 2010) . Although inducible expression of Tat in this model is not equivalent to human HIV-infection and does not induce the same host response, this model displays extensive neuropathological changes such as loss of cerebellum and cortex, neuronal death (apoptosis), astrocytosis, degeneration of neuronal dendrites, and the CNS infiltration of monocytes and activated T lymphocytes (Kim et al., 2003) . In addition, this model exhibit significant changes in DAT function and expression (Perry et al., 2010) and recapitulates many aspects of cognitive impairments observed in HIV infected individuals such as impairments of reversal learning, novel object recognition, and spatial learning and memory (Carey, Sypek, Singh, Kaufman, & McLaughlin, 2012; Fitting et al., 2013; Paris, Singh, Ganno, Jackson, & McLaughlin, 2014) , and increased cocaine-conditioned place preference (Paris, Carey, et al., 2014) . Therefore, this model offers specific advantages to study Tat-mediated dysregulation of DA transmission. In addition to Tat, recent studies show that other viral proteins, such as gp120 and Nef also influence DAT activity (Acharjee et al., 2014; Hu, Sheng, & Rock, 2013) .
Tat interacts with human DAT directly
A question of significant interest is whether Tat interacts with DAT protein directly through protein-protein interaction. Studies demonstrated that Tat protein interacts biophysically and biochemically with DAT as a direct protein-protein interaction, which was validated by surface plasmon resonance (SPR) analysis (Zhu et al., 2009 ), co-immunoprecipitation (CO-IP) and glutathione S-transferase (GST)-Tat (350 nM recombinant Tat 1-86 ) pull down assays (Midde et al., 2013) . These investigations greatly support the later work with mapping Tat binding sites in hDAT. Although several forms of Tat (Tat 1-72 , Tat 1-86 and Tat 1-101 ) are available for laboratory studies, recombinant Tat 1-86 has been extensively used to study its neuropathological effects on the CNS (Aksenova et al., 2006; Bruce-Keller et al., 2003; Nath et al., 1996; Zhu et al., 2009 Zhu et al., , 2015 . Evidence shows that Tat 1-72 , Tat 1-86 , and full length Tat 1-101 released from Tat-expressing cells exhibit equivalent inhibitory effect on DAT function (Midde et al., 2013) . There are two clade B types of Tat 1-86 , including the released Tat 1-86 from Tat-expressing cells (Li et al., 2008; Midde et al., 2013) and the recombinant Tat 1-86 (Diatheva, Fano, Italy or ImmunoDX, Woburn, MA) Sun et al., 2017) . Since the recombinant Tat is considerably less potent than Tat released from Tat-expressing astrocytes (Li et al., 2008; Li et al., 2009 ), higher concentrations of this commonly used recombinant Tat protein may be required to adequately mimic the effects of Tat constitutively produced in the HIV-1 infected cells. However, the advantage of using the recombinant Tat is that it is a purified protein and can be used at exact molar concentrations for the designed experiments. Peptides derived from the first exon of Tat, including Tat 46-60 , Tat 37-72 , and Tat 31-61 , have been found to cause neurotoxicity (Nath et al., 1996; Philippon et al., 1994) . Particularly, evidence shows that the cysteine-rich domain (residues 22-37) in the first exon of Tat is critical for the biological function of Tat (Bertrand, Aksenova, Mactutus, & Booze, 2013; Debaisieux, Rayne, Yezid, & Beaumelle, 2012) . Mutation of Tat cysteine 22 to glycine completely eliminated the inhibitory effect of wild type recombinant Tat 1-86 (500-1000 nM, final concentration) on DAT function Zhu et al., 2009) . Thus, understanding the functional relevance of additional residues in Tat on modulation of DAT will provide useful feedback for identifying the recognition binding sites on hDAT for Tat protein.
Computational structural models of dopamine transporter and Tat interaction
As described above, Tat interacts directly with DAT (Midde et al., 2013; Zhu et al., 2009) , which makes it feasible to perform computational modeling for studying the interaction of Tat with DAT. It is essential to understand how hDAT interacts with Tat at a molecular level, especially the detailed hDAT-Tat binding mode. However, it would be a grand challenge to determine an X-ray crystal structure of hDAT-Tat binding complex in the physiological membrane environment. In fact, X-ray crystal structure is not available even for hDAT itself. Nevertheless, state-of-the-art molecular modeling techniques have provided useful tools to model the possible hDAT-Tat interaction. To understand how hDAT interacts with Tat, one first needs to know the three-dimensional (3D) structure of hDAT. Early homology modeling studies on 3D structures of hDAT were performed by using the X-ray crystal structure of Na + /H + antiporter or lactose permease (LacY, e.g. PDB entry of 1PV7 with a resolution of 3.6 Å) as a template. It is now known that the templates used in early modeling studies are not suitable for homology modeling of any member of the neurotransmitter sodium symporters (NSS) family to which DAT belongs (Huang & Zhan, 2007; Krishnamurthy & Gouaux, 2012; Masson et al., 1999) . X-ray crystal structure of leucine transporter from Aquifex aeolicus (LeuT Aa ) was considered a more suitable template for modeling the NSS family (Singh, Piscitelli, Yamashita, & Gouaux, 2008; Yamashita, Singh, Kawate, Jin, & Gouaux, 2005) of transporters to which DAT belongs. The LeuT Aa -based first homology model of hDAT was first reported in 2007Several computational and experimental studies on the structures of hDAT and associated transporters have addressed some critical questions of the NSS members (Gedeon, Indarte, Surratt, & Madura, 2010; Gelman et al., 2012; Guptaroy et al., 2009; Henry et al., 2011; Huang, Gu, & Zhan, 2009; Huang & Zhan, 2007; Koldso et al., 2011; Shan, Javitch, Shi, & Weinstein, 2011; Stockner et al., 2013; Sucic et al., 2010) . Although the LeuT Aa -based 3D structures of hDAT have been proven as a valuable model in predicting the hDAT-Tat interaction (Midde et al., 2013) , the LeuT Aa -based 3D structures of hDAT are not perfect due to the fact that the sequence identity between LeuT Aa and hDAT is less than 25%. The recent hDAT structural models reported in literature were obtained from homology modeling using the X-ray crystal structure (Penmatsa, Wang, & Gouaux, 2013 of Drosophila DAT (dDAT). Interestingly, the dDAT-based hDAT model in the outward-open state is essentially the same as the corresponding state of the LeuT Aa -based model, but provides additional finer details. Therefore, the dDAT-based hDAT structure may be considered as a refined 3D model of the LeuT Aa -based hDAT structure (Yuan, Huang, Zhu, & Zhan, 2016) . The sequence identity between hDAT and dDAT is 46%, which is sufficient for constructing a satisfactory homology model (Nayeem, Sitkoff, & Krystek, 2006; Sali, Potterton, Yuan, van Vlijmen, & Karplus, 1995) . Through the dDAT-modeled hDAT structures, further computational modeling studies aimed to understand how Tat protein via its recognition binding sites on hDAT interacts with hDAT (Midde et al., 2013 Yuan et al., 2015; Yuan, Huang, et al., 2016) . This modeling reveals that the DA uptake is associated with the conformational conversion of hDAT from the outward-open state to the outward-occluded state and then to the inward-open state (Yuan, Huang, et al., 2016) . Furthermore, the computational modeling prediction indicates that Tat protein directly interacts with hDAT in the outward-open state, which is validated by experimental studies (Midde et al., 2013 . Based on this principle, antagonizing DAT-mediated DA uptake may be achieved by either blocking the DA binding or preventing the conformational conversion of hDAT after DA binding (Yuan, Huang, et al., 2016) . According to the 3D model of hDAT-Tat interaction complex, the binding of Tat with hDAT would permit a way of binding without competing with DA binding, but preventing the conformational conversion from the outward-open state to the other states (outward-occluded and inward-open states). Therefore, the Tat binding should not compete with the DA binding. Further, the computationally predicted hDAT-Tat binding model revealed the roles of some key residues (such as Y88, K92, Y470, and H547) of hDAT in binding with Tat, suggesting that amino-acid substitution on any of these residues will weaken the hDATTat binding. Further, in a most recently reported study, computational modeling indicated that residue H547 of hDAT plays a crucial role in not only the hDAT-Tat binding, but also DA uptake by hDAT, predicting that the H547A mutation will not only considerably attenuate Tat-induced inhibition of DA uptake, but also significantly increase the V max of hDAT for DA uptake. The above computational models and predictions were followed by extensive experimental tests that support the models and predictions as discussed below.
Pharmacological validation of the key residues on dopamine transporter for Tat binding
To obtain experimental evidence for the mode of binding predicted by the 3D structural model of hDAT binding with Tat, the effects of Tat on DA reuptake by hDAT bearing mutations of the identified key residues have been validated and refined by site-directed mutagenesis and pharmacological assays Yuan, Huang, et al., 2016) . This work was recently highlighted in the HIV research by Nature Chemical Biology (Bucci, 2015) . Through the integrated computational modeling prediction and experimental validation, key residues can be identified in hDAT with which Tat interacts, which are critical for Tat-induced inhibition of DAT. In general, in vitro exposure of cell lines expressing hDAT to 140 nM Tat 1-86 displayed a 30% decrease in [ 3 H]DA uptake in WT hDAT (Midde et al., 2013 Quizon et al., 2016) . One may expect that mutations of identified binding residues on hDAT for Tat would attenuate the Tat-induced inhibition of DA transport. One caveat is that Tat-induced inhibition of hDAT in cell system may not reflect hDAT-Tat interaction in HIV infected human brain and does not measure the biological effects on HIV-1 Tat protein on hDAT function. However, through this in vitro model we can explore the molecular mechanism(s) of Tat inhibition on the DA uptake by DAT and interactions with cocaine.
3.3.1. The functional influences of Y88, K92 and Y470 of hDAT on DA transport process
The amino acid sequence of hDAT has 12 transmembrane (TM) helices. According to the computationally modeled hDAT structures Yuan et al., 2015) , TM1, TM6 and TM10 are crucial for conformational conversion of DA transport process from the outward-open to the outward-occluded state of hDAT. This is consistent with the previous studies showing R85-D476 (between TM1 and TM10) salt bridge as a key indication for the conformational conversion (Gedeon et al., 2010; Huang & Zhan, 2007; Manepalli, Surratt, Madura, & Nolan, 2012; Schmitt & Reith, 2011) . Therefore, any structural changes involving the intermolecular interactions of TM1, TM6 and/or TM10 are expected to influence the conformational conversion, thereby altering DA uptake by hDAT. Interestingly, computational modeling using the dDAT-based hDAT model predicts that Tat binds most favorably with the outward-open state of hDAT. Further analysis of the molecular dynamics simulations of the hDAT-Tat binding structure revealed that Y88, K92, and Y470 of hDAT are key residues involved in the intermolecular interaction between hDAT and Tat . Among these residues, K92 (TM1b) interacts with D313 (TM6a) side chains forming a favorable salt bridge during the molecular dynamics simulations on the hDAT-DA binding structures, which is necessary for the conformational conversion of hDAT during the DA uptake process. As a result, elimination of the K92-D313 salt bridge is expected to impair/slow down the DA uptake process. This computational prediction has been validated by site-directed mutagenesis and in vitro pharmacological assays. For example, mutations of K92 (K92M) and D313 (D313N) (Chen, Zhen, & Reith, 2004) decrease the V max for DA uptake by 70% and 80%, respectively, relative to wild type hDAT. In addition, Y470 residue (in TM10) of hDAT is a key component of a hydrophobic region, which is critical for stabilizing the compact structure of hDAT. As a result, significant change in the hydrophobic property or shape of Y470 by mutations (Y470H or Y470A but not Y470F) could decrease the V max for DA uptake (Midde et al., 2013 . The aromatic ring of the Y88 side chain is sandwiched between TM1b and extracellular loop 4 (EL4) in a hydrophobic region as a stable intermolecular structure of hDAT. As a result, mutation of Y88 (Y88F) retains the reuptake function of hDAT without change in the V max .
The functional influences of H547 of hDAT on DA transport process
In addition to R85-D476 salt bridge, computational modeling prediction has revealed that a stable structural motif (Y548-Y470-Y551, denoted as YYY motif) is also an essential structural feature for the conformational conversion of hDAT during DA transport process . This YYY motif contains a typical U-turn loop with a hydrophobic region which is associated with extracellular loop 6 (EL6) and TM10a. Any amino-acid-based structural changes that destabilize the YYY motif would impair the formation of the R85-D476 salt bridge, which then influences the conformational conversion associated with the DA transport process. As described above, mutation of Y470 (Y470H) that destabilizes the YYY motif by disrupting the hydrophobic interaction dramatically decreases the V max for DA uptake (Midde et al., 2013 . Interestingly, mutations of H547 residue that is adjacent to Y548 of the YYY motif is also expected to significantly affect the stability of the YYY motif . The H547A mutant improves the strength of the R85-D476 salt bridge that is comparable to that in wild type hDAT, whereas the salt bridge is broken in the H547P and H547D, thus, affecting the DA transport by hDAT . The computational modeling predictions were validated pharmacologically. For example, the V max for DA uptake is increased by 196% in H547A and decreased by 99% in H547P and 60% in H547D, respectively, but not altered in H547R .
Attenuation of Tat-induced inhibition of DA transport
Through the computational modeling and molecular dynamics simulations, it is possible to identify the most favorable hDAT-Tat binding mode, including a cation-π interaction involving Y470 of hDAT and two hydrogen-bonding interactions involving hDAT residues Y88 and K92 . Based on this prediction, the cation-π interaction between hDAT and Tat would be eliminated by Y470H and Y470A mutations but not Y470F. Mutations of K92 (K92M) and Y88 (Y88F) are expected to inhibit the Tat binding with minimal influence by the mutated Y88. Accordingly, in vitro pharmacological studies reveal that exposure to 140 nM Tat 1-86 induces a 30% reduction of the specific DA uptake in wild type hDAT, which is completely attenuated in mutants Y470H, Y470A, and Y88F, but not in Y470F mutant (Midde et al., 2013 . In addition, both the side chain and backbone of H547 residue on hDAT forms a hydrogen bond with residue R49 of HIVTat , which is expected to be broken with the H547 mutation. As a result, Tat 1-86 (140 nM)-induced inhibition of the specific [ 3 H]DA uptake in wild type hDAT is attenuated in H547 mutants (H547A, H547P, and H547D) and associated hDAT residue Y551H. Based on the modeled Tat-hDAT binding structure, a total of 20 residues of hDAT were predicted to be key residues for the hDAT-Tat interaction . Table 1 shows a summary of the partial results of the different effects of mutants on basal DA uptake and Tatinduced inhibition of DA transport, which can be categorized as: 1) retaining normal DA uptake but attenuating Tat's inhibitory effect (Y88F and H547R) or 2) not affecting Tat's inhibitory effect (Y470F); 3) reducing DA uptake and attenuating Tat's effect (Y470H, Y470A, K92 M, H547P, and H547D); and 4) enhancing normal DA uptake while attenuating Tat's effect (H547A). Thus, understanding the binding residues on hDAT for Tat will provide a mechanistic basis for identifying targets for developing compounds that specifically block Tat binding site(s) in DAT or diminish the Tat binding affinity by allosteric modulation.
Allosteric modulatory effect of Tat protein on DA transport
An estimated prevalence of comorbid HIV infection and drug abuse is about 40-70% of HIV positive individuals. Drugs of abuse, such as cocaine, have been shown to increase the incidence of HAND and exacerbate the severity of HAND by enhancing viral replication while there is no FDA-approved therapy for cocaine addiction. Cocaine is thought to mediate most of its behavioral and rewarding effects via blockade of the DAT and the resulting elevation in extracellular brain DA levels (Dutta, Zhang, Kolhatkar, & Reith, 2003) . Interplay of Tat and cocaine augments synaptic DA levels and Tat release by inhibiting DAT activity (Ferris et al., 2010; Zhu et al., 2009) , which may contribute to the progression of HAND underlying the cognitive deficits in HIV-1 positive cocaine-using individuals (Chang et al., 2008; Wang et al., 2004) . Therefore, there is a pressing need to define the molecular mechanism(s) by which Tat through their recognition binding sites on hDAT potentiates cocaine-induced inhibition on DAT function, thereby leading to dysfunction of the DA system. Attenuating inhibitory effects of Tat and cocaine on DA transport are important for preventing the DAT-mediated dysfunction of DA system in HIV infected patients with cocaine abuse.
Cocaine and Tat protein differentially interact with hDAT
Molecular model for DAT binding of cocaine constructed from the high-resolution structure of the bacterial transporter homologue LeuT suggests that the binding site for cocaine is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrate, DA (Beuming et al., 2008) . This cocaine-DAT model is validated by detailed mutagenesis and by trapping the radiolabeled cocaine analog [ 3 H]CFT in the transporter, which demonstrates the molecular basis for the competitive inhibition of DA transport by cocaine. Moreover, according to further molecular modeling and dynamics simulations, the cocaine competes with DA for binding with DAT (Huang et al., 2009 ). Taken together, these studies conclude that it is impossible to generate a competitive inhibitor of cocaine binding that treats cocaine addiction without itself inhibiting DA uptake. In contrast, with respect to Tat protein, Tat-induced inhibition of DAT is mediated by binding to allosteric binding site(s) on DAT, not by interacting with the DA uptake site Zhu et al., 2009 Zhu et al., , 2011 (Yu et al., 2013) .
Allosteric modulation of DAT by cocaine and Tat
In general, transporter ligands that interact with neurotransmitter transport are typically classified into two categories: cocaine-like competitive inhibitors and amphetamine-like substrates (Schmitt, Rothman, & Reith, 2013) , which increase extracellular monoamine levels and display addiction liability similar to that of cocaine. In addition to competitive inhibitors and substrates of transporter, there is a growing interest in allosteric modulators of DAT. Allosteric sites on hDAT may represent novel drug targets that display neutral cooperativity with the classical DA uptake site. If inhibition of DA uptake by cocaine or Tat is the result of an allosteric mechanism, it would be possible, at least in theory, to generate an allosteric modulator that might attenuate cocaine and Tat binding to DAT without affecting DA transport for treatment of individuals with comorbid HIV infection and cocaine use. DAT-mediated DA transport is a dynamic DA translocation process, which is regulated by three typical conformational states: outward-open → outward-occluded → inward-open (Beuming et al., 2008; Kniazeff et al., 2008; Zhao et al., 2010) . The substrate (DA) transport process is associated with the transporter protein conformational changes. Conformational transitions via substrate-and ligandbinding sites on DAT are responsible for allosteric modulation of DAT (Shan et al., 2011) . Cocaine and Tat protein preferentially stabilize the DAT in the outward-open state, resulting in reduction of DA uptake by directly blocking DA uptake site (Loland, Norregaard, Litman, & Gether, 2002; Reith, Berfield, Wang, Ferrer, & Javitch, 2001; Yuan et al., 2015; Yuan, Quizon, et al., 2016) . Generally, the processes of the conformational changes in DA transport involve conversions between outwardopen and inward-open states (Zhao et al., 2010) . In support of an allosteric modulation for cocaine binding, previous studies have reported that mutations of several residues in DAT produce differential effects on cocaine and DA binding (Chen et al., 2006; Chen, Han, & Gu, 2005; Lin & Uhl, 2002; Loland, Granas, Javitch, & Gether, 2004; Uhl & Lin, 2003) . However, the marked decrease in affinity for cocaine by mutating these residues is the result of an altered conformational equilibrium of DAT toward an inward-open conformation, rather than because of disruption of a direct interaction between the identified residues and cocaine (Loland et al., 2002 (Loland et al., , 2004 Sen, Shi, Beuming, Weinstein, & Javitch, 2005) . Given that Tat protein and cocaine synergistically impair DAT function, a detailed understanding of the interplay between Tat and cocaine in disrupting DAT-mediated DA dysregulation may provide therapeutic insights into HAND in concurrent cocaine abusers. As described above, several key residues have been identified in hDAT, which are critical for Tat-induced inhibition of DAT and transporter conformational changes. Interestingly, compared to WT hDAT, mutations in these residues lead to an increase in affinity for cocaine (Midde et al., 2013 Quizon et al., 2016) binding sites (Moritz et al., 2013; Norregaard, Frederiksen, Nielsen, & Gether, 1998) , but decreasing DA uptake (Loland, NorgaardNielsen, & Gether, 2003 (Midde et al., 2013 Quizon et al., 2016) . By using a hDAT homology model to dock Tat into the transporter and MD simulations to probe the conformational state of hDAT bound to Tat, it was found that Tat can only bind to the outward-open structure with favorable binding energies . Therefore, it was predicted that Tat binding would block the entry pathway of the DA substrate, thereby inhibiting DA clearance from the presynaptic cleft. These findings suggest that Tat protein via its recognition residues in hDAT produces inhibition of DA transport by altering transporter conformational transitions.
Developing biological probes for attenuating Tat binding to DAT
Evidence showing Tat-induced allosteric modulation of DA transport provides a molecular basis for developing allosteric modulatory molecules that decrease the affinity and maximal binding potential of cocaine and Tat. This could be a viable approach for treatment of cocaine-and Tat-induced dysfunction of DA system. Identifying suitable molecular probes and performing proof of concept studies is of great scientific and clinical interest. Recent studies have reported that a novel quinazoline series (SRI-compounds) of monoamine transporter ligands, functions as partial antagonists of DA uptake without the full inhibitory profile that is typical of classic competitors of DAT (Pariser et al., 2008; Rothman et al., 2015; Rothman, Dersch, Ananthan, & Partilla, 2009; Schmitt et al., 2013) . There are a number of advantages in using allosteric modulators of DAT as preferred therapeutic agents over classic competitor of the DA uptake site. Such allosteric modulators could potentially attenuate the effect of cocaine and Tat on DAT while having minimal effects on the physiological DA transmission. Although it is still unclear how the SRI-compounds through their interaction with allosteric modulatory sites on hDAT alter the affinity and maximal binding potential of cocaine and Tat, recent studies have demonstrated that the SRI-compounds attenuate the inhibitory effects of cocaine and Tat on DA uptake and binding (Sun et al., 2017; Zhu et al., 2011) . For example, compared to indatraline, a competitive inhibitor for DAT, SRIcompounds produce~40% reduction of the specific [ (Sun et al., 2017; Zhu et al., 2011) . These findings suggest that SRI-compounds display a partial antagonism on DA transport in an allosteric modulation manner. Furthermore, SRI-compounds were evaluated in a dissociation assay, in which the dissociation is initiated by blocking the forward reaction with 10 μM cocaine, a concentration high enough to occupy all DAT binding sites followed by assessing the cocaine-mediated dissociation rate of [ . These findings further demonstrate that SRIcompounds modulate the conformation of DAT by binding to a site to which cocaine or WIN 35,428 does not bind, thereby leading to alteration of the kinetics of the [ As described above for Tat-mediated allosteric modulation, one recent study reported that SRI-30827 attenuated 40 nM recombinant Tat 1-86 -induced inhibition of [ 3 H]WIN 35,428 binding, indicating that Tat binding to DAT can be modulated by allosteric ligands (Sun et al., 2017) . Computational docking study shows that SRI-30827 interacts with hDAT extracellular loop 6 that contacts directly with Tat and can partially inhibit DAT uptake function (Sun et al., 2017) . Since the conformational changes in DA transport process involve conversions between the outward-and inward-open conformations (Zhao et al., 2010) , further docking studies were performed using homology models of hDAT at the different conformational states and two SRI-compounds. These studies revealed that the SRI-compounds could only fit into the outward-open hDAT model. Interestingly, the docked pose of the ligands at hDAT-Tat complex reveal that compounds such as SRI-30827 could potentially influence the conformation of residues Tyr470 and Tyr88 in the EL6 region, and thus likely modulate the binding of Tat on hDAT via an allosteric modulatory mechanism. However, it is still unclear whether the attenuation of Tat-induced inhibition of [ 3 H]WIN 35,428 binding by SRI-30827 is through direct interaction with Tat binding site or other allosteric binding sites. Recent studies have demonstrated that DAT tyrosine 470 and 88 replaced by histidine (Y470H) or phenylalanine (Y88F) retain the normal surface DAT expression and attenuate Tat-induced inhibition of DA transport (Midde et al., 2013 . Further, mutating these two residues prevented zinc-induced regulation of DA uptake and WIN 35,438 binding (Midde et al., 2013 , which may suggest that these two residues are critical for Tat allosteric modulation of DAT. According to the previous modeling results, in the outward-open hDAT conformation, Y470 extends to the extracellular region where it interacts directly with Tat residues . In the SRI-compound docked models, SRI compounds may potentially influence the conformation of residues Tyr470 and Tyr88 with EL6 region, and thus likely modulate the binding of Tat on hDAT via an allosteric modulatory mechanism. Hence, although SRI-compounds may not interact directly with either Tyr470 or Tyr88 for competing with Tat binding, they can weaken the Tat DAT binding by changing the DAT conformation allosterically. One possibility is that Y470H-and Y88F-mediated transporter conformational transitions may contribute to these changes in cocaine-mediated inhibition of DA uptake and dissociation in these mutants. Taken together, considering both Y470 and Y88 are associated with hDAT-Tat interactions, developing compounds directly targeting the specific binding sites on hDAT for Tat could provide a viable approach for treatment of Tat-induced dopamine dysfunction. Alternatively, developing DAT-based allosteric modulator interacting with the specific residues that are structurally distinct from Tat binding sites would be another possible therapeutic approach.
Reversible Tat-induced dysfunction of dopamine transporter
Given that Tat induces dysregulation of DA system by inhibiting DA transport, it is critical to define whether the inhibitory effects of Tat on DAT function is reversible, since the dysfunction occurs long before dopaminergic neuron loss and the development of HIV-associated dementia (Wang et al., 2004) . As such, effective prevention of the early effects of Tat exposure in the brain of HIV-infected individuals is a potentially promising approach to prevent Tat-mediated neurocognitive impairments. This will provide insight into understanding the most appropriate therapeutic window during early HIV infection.
Tat regulates DAT trafficking
The efficacy of DA uptake largely depends on DAT expression in the plasma membrane, which is dynamically modulated by a trafficking mechanism (Zhu & Reith, 2008) . Particularly, dynamic cell surface localization of DAT is regulated by cellular signaling pathways and endocytotic trafficking (Melikian, 2004) . It has been demonstrated that Tat inhibits DA uptake in a time-and concentration-dependent manner (Zhu et al., 2009) . Particularly, a 15-min exposure of rat synaptosomes to 1 μM recombinant Tat 1-86 induced a rapid and reversible decrease in the V max of [ 3 H]DA uptake without changes in total DAT levels (Zhu et al., 2009) (Zhu et al., 2009) , providing evidence that a short time exposure to Tat does not decrease the DAT turnover rates. Furthermore, after 15-min exposure of rat striatal synaptosomes to 1 μM recombinant Tat 1-86 , DAT expression was decreased by 46% in plasma membrane and increased by 49% in intracellular compartment without changes in total DAT levels (Midde, Gomez, & Zhu, 2012) . These data indicate that exposure to Tat results in a redistribution of DAT from the cell surface to intracellular compartments (i.e. internalization) and that loss of DAT from the plasma membrane is responsible for the decrease in V max observed after Tat exposure. In contrast, Perry et al. (2010) reported that exposure of rat mesencephalic neurons or PC12-hDAT cells to 120 nM recombinant Tat 1-86 induces a slight decrease in DAT-mediated DA uptake at 15 min, however, the DA uptake was significantly increased by 4-fold at 30 min and 2-fold after 24 h, respectively (Perry et al., 2010) . Interestingly, using total internal reflection fluorescence assay Perry et al. identified that DAT expression in plasma membrane is increased after 30-min exposure of PC12 hDAT culture to 120 nM recombinant Tat 1-86 , whereas 24-h Tat exposure increases DAT protein synthesis, suggesting that Tat in vitro influences DAT function and expression through different mechanisms (Perry et al., 2010) .
The elevated DAT levels were observed in the postmortem brain tissue from HAND patients (Gelman et al., 2006) . It is important to correlate the in vitro findings with in vivo evidence of dopaminergic dysfunction in the context of HAND. Perry et al. reported that striatal DAT expression levels are increased in iTat mice compared to wild type control mice after 7-day administration of doxycycline, suggesting that in vivo Tat exposure alters DAT levels. However, this study did not examine the DAT levels in these animals in the absence of Tat induction, such as saline control groups (Perry et al., 2010) . Moreover, it has been reported that the HIV-1 Tg rats exhibit significantly enhanced V max values of [ 3 H]DA uptake into rat synaptosomes of both prefrontal cortex and striatum , which is opposite to the findings showing decreased DAT reuptake in vitro (Zhu et al., 2009) . The increased V max in the prefrontal cortex and striatum was accompanied by distinctly different alterations in DAT expression in the plasma membrane in a brain region-specific manner . Particularly, decreased B max values of [ 3 H]WIN 35,428 binding was observed in the striatal plasma membrane fraction, indicating an increase in uptake turnover rate in HIV-1 Tg rats. Thus, these findings suggest that neuroadaptive changes in DAT function are evidenced in animal models with genetically expressing HIV viral proteins, perhaps in compensation for viral protein-induced abnormal dopaminergic transmission. Thus, these in vitro studies suggest that Tat-induced inhibition of DAT-mediated DA uptake is reversible, which provides insight into understanding the most appropriate therapeutic window during early HIV infection.
Tat regulates DAT function by affecting subcellular signaling
The dynamic regulation of DAT function is under the control of complex processes involving subcellular signaling, protein-protein interaction, substrate pretreatment, and interaction with presynaptic receptors (Zhu & Reith, 2008 (Richards & Zahniser, 2009) . Therefore, compared to amphetamine, Tat produces a similar regulatory effect on DAT uptake function through a PKC-dependent mechanism. Moreover, as described above, His547 in hDAT is a key residue for Tat binding . In addition, it was found that promoting PKC phosphorylation of DAT with PMA, a PKC activator, results in 40% and 60% reduction of DA uptake in WT hDAT and H547A, respectively. Similarly, preventing PKC phosphorylation of DAT with BIM produces a 98% and 42% increase in DA uptake in WT hDAT and H547A, respectively. This suggests a differential sensitivity to PMA-or BIM-induced activation or inhibition of DAT function between WT hDAT and H547A. One possibility is that mutation of His547 alters basal levels of PKC-mediated phosphorylation of DAT, thereby resulting in the enhanced DA uptake. Recent studies demonstrate that the serine-7 residue in DAT is critical for PKC-dependent DAT phosphorylation (Moritz et al., 2013) , and the alanine mutation of serine-7 results in an increase in DA uptake relative to WT DAT (Moritz et al., 2015) . As the PKC phosphorylation sites on cytoplasmic domain (intracellular side) of hDAT are structurally far away from the residue H547 on the extracellular side of hDAT (Midde et al., 2013; Yuan, Quizon, et al., 2016) , the H547A mutation is likely to regulate the PKCmediated phosphorylation by allosteric effect. In addition to PKC signaling, evidence shows that inhibition of GSK-3β stabilizes β-catenin and increases the number of DA neurons from ventral mesencephalon precursor (Castelo-Branco, Rawal, & Arenas, 2004) . Perry et al. (2010) reported that 120 nM recombinant Tat 1-86 significantly elevates plasma membrane-localized DAT expression and DA transport by activation of glycogen synthase kinase-3 (GSK-3) signaling pathway (Perry et al., 2010) . GSK-3β inhibition prevented Tat-induced increases in membrane DAT and membrane calpain activity, highlighting mechanisms by which GSK-3β inhibitors may confer neuroprotective benefits for dopaminergic symptoms in HAND (Ances, Letendre, Alexander, & Ellis, 2008; Dewhurst, Maggirwar, Schifitto, Gendelman, & Gelbard, 2007) .
Collectively, these observations may suggest the potential regulatory pathways for DAT compensatory response to in vitro Tat exposure by 1) enhancing reuptake capacity, 2) increasing DAT turnover rate, 3) trafficking DAT to the plasma membrane, and 4) changing subcellular signaling pathways. Although there is limited evidence supporting the conclusion, these studies provide novel insights for future investigations of Tat-induced dysregulation of dopaminergic transmission by DAT. Long lasting exposure to viral proteins and elevated DA eventually lead to dysregulation of DAT-mediated DA transmission that potentiates HAND severity and accelerates its progression.
Conclusion
There are two outstanding reviews that discuss recent investigations regarding the interactions between the Tat protein and dopaminergic neurotransmission (Gaskill et al., 2017; Purohit et al., 2011) . What has emerged from the extensive studies is a clear link between perturbation of dopaminergic transmission by exposure of the CNS to Tat and the risk of HAND. Given the importance of DAT in DA homeostasis and synaptic DA transmission, this review highlights the impact of DAT on the Tatinduced dysregulation of DA system. Most importantly, Tat and cocaine synergistically elevate synaptic DA levels by acting directly on hDAT, which ultimately leads to dysregulation of dopamine transmission. This process provides a mechanistic explanation for why cocaine abuse increases the incidence of HAND and exacerbates its severity. Fig. 1 provides a summary cartoon of what has been described in this review of recent investigations, which highlights a vicious circle of HIV-1 infection-induced impairment of dopaminergic neurotransmission. There appears to be multiple mechanisms by which DAT can compensate for Tat-induced dysregulation of DA system, which maintain a constant level of DA at the synaptic cleft. In the past few years, much progress has been made in identifying the intermolecular interactions of Tat and hDAT and their impact on DAT-mediated DA neurotransmission. Allosteric modulators may have therapeutic utility in HAND, not only by preventing Tat binding to hDAT but also by reversing DAT function. However, fundamental questions remain as to the biological form of Tat protein, its concentration in the CNS, and how Tat influences DATmediated DA system in the early stage of HIV infection. Through integrated computational modeling and experimental approaches, the unique residues on hDAT are identified and validated; however, these binding residues for Tat may not reflect the hDAT-Tat binding mode in the brains of HIV infected patients. To explore the role of the identified residues in HIV infection-induced neurocognitive deficits in inducible Fig. 1 . Theoretical representation of the role of hDAT in HIV infection-impaired dopaminergic neurotransmission. HIV crosses the blood brain barrier (BBB) in the early stage of HIV infection ① and viral replication takes place in macrophages (Mɸ) ② in the basal ganglia. While virus replication takes place in macrophages, viral proteins are released ③, which damage DA neurons. Tat and cocaine synergistically elevate DA levels by directly blocking DA transport process ④. The elevated DA ⑤ further stimulates viral replication and Tat release by activating DA receptors in macrophages ⑥. In addition, DAT activity can be regulated through trafficking dependent and/or independent mechanisms as well as phosphorylation of subcellular signaling pathways ⑦, compensating for Tat-induced increase in DA levels and thereby maintaining a constant level of DA at the synaptic cleft.
Tat transgenic mice is an essential task in future studies. Notably, the prefrontal cortex is a critical brain region for higher cognitive function (Dalley, Cardinal, & Robbins, 2004; Miller & Cohen, 2001; Ridderinkhof, van den Wildenberg, Segalowitz, & Carter, 2004) , where norepinephrine (NE) transporter (NET) is more concentrated than the DAT and plays a primary role in reuptake of DA (Moll et al., 2000; Moron, Brockington, Wise, Rocha, & Hope, 2002) . The serotonin transporter has a low affinity to effectively take up and transport DA at physiological levels, whereas the NET can transport DA and NE (Horn, 1973; Raiteri, Del Carmine, Bertollini, & Levi, 1977) . For these reasons, it is likely that Tat-induced dysfunction of DA system could be mediated by inhibition of both DAT and NET, which is evidenced by increased prevalence of comorbid psychiatric conditions related to NE and serotonin dysregulation in HIV infected patients (Adams, Zacharia, Masters, Coffey, & Catalan, 2016; Jallow, Ljunggren, Wandell, Wahlstrom, & Carlsson, 2017; Miners et al., 2014; Mirani et al., 2015) . Determining the mechanistic basis underlying the Tat interactions with DAT/NET is currently underway because it may reveal novel therapeutic possibilities for preventing the increase in comorbid conditions as well as HAND. Overall, further understanding of the molecular mechanism(s) of Tat-induced impairment of DA transport process will greatly provide a novel mechanistic basis for developing compounds that specifically attenuate cocaine and Tat binding site(s) in hDAT to normalize DA transmission to physiological levels in HIV-infected cocaine-using patients. In summary, the findings presented herein raise the exciting possibility of potential therapeutic intervention for HIV infected patients with concurrent cocaine abuse. Proof of this concept could emerge from efforts directed toward discovery and development of candidate in vivo probe molecules with the desired allosteric modulation profiles coupled with favorable drug-like attributes. The effectiveness of an early intervention for HAND to preserve neurocognitive functions in HIV-infected individuals may ultimately depend on a treatment approach that combines compound(s) that specifically attenuate Tat binding site(s) in DAT with antiretroviral therapy, without affecting the normal function of DAT.
